EQUITY RESEARCH MEMO

Healgen Scientific

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)55/100

Healgen Scientific is a Houston-based diagnostics company specializing in FDA-cleared rapid tests for infectious diseases and drug abuse. Founded in 2007, the company offers products such as the Healgen® Rapid Check® COVID-19/Flu A&B Antigen Test, Accurate Fentanyl Rapid Tests, and multi-drug urine screens for both professional and home use. With a focus on point-of-care and at-home testing, Healgen aims to address critical public health needs including respiratory infections and the opioid crisis. As a private company, Healgen operates with a lean profile but has established a foothold in the diagnostics market through regulatory clearances and a broad product portfolio.

Upcoming Catalysts (preview)

  • Q3 2026Expansion of COVID-19/Flu A&B Test Distribution70% success
  • Q4 2026FDA 510(k) Clearance for New Drug Test Panel60% success
  • Q2 2026Partnership with National Retail Pharmacy Chain50% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)